If you have been reading about lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Salvia divinorum was first recorded in print by Jean Basset Johnson in 1939 while he was studying Mazatec shamanism. He later documented its use and reported its effects through personal testimonials of users. It was not until 2002 that Bryan Roth and his team identified the psychoactive mechanism. Gordon Wasson tentatively postulated that the plant could be the mythological pipiltzintzintli, the "Noble Prince" of the Aztec codices. Wasson's speculation has been the subject of further debate amongst ethnobotanists, with some scepticism coming from Leander J. Valdés, and counterpoints more supportive of Wasson's theory from Jonathan Ott. The identity of another mysterious Aztec entheogen, namely that of poyomatli, has also been suggested as being Salvia divinorum. Here too there are other candidate plants, notably cacahuaxochitl (Quararibea funebris),
SDMA, also known as 3,4-methylenethiooxy-N-methylamphetamine (3T-MDMA) or as MY100, is a putative entactogen of the phenethylamine and amphetamine families related to 3,4-methylenedioxy-N-methylamphetamine (MDMA). It is the analogue of MDMA in which the oxygen atom at the 3 position within the 3,4-methylenedioxy substitution has been replaced with a sulfur atom to give a 1,3-benzoxathiole rather than 1,3-benzodioxole ring system. The drug is also the N-methyl derivative of 3,4-methylenethiooxyamphetamine (SDA; 3T-MDA). SDMA is of interest for potential therapeutic use.
===== Medicines for curative treatment ===== Artemether Artemether/lumefantrine (artemether + lumefantrine) Artesunate Artesunate/amodiaquine (artesunate + amodiaquine) Artesunate/mefloquine (artesunate + mefloquine) Artesunate/pyronaridine tetraphosphate (artesunate + pyronaridine tetraphosphate) Artesunate + sulfadoxine/pyrimethamine (Co-packaged) Chloroquine Dihydroartemisinin/piperaquine phosphate (dihydroartemisinin + piperaquine phosphate) Primaquine Quinine
=== Autosamplers === Large numbers of samples can be automatically injected onto an HPLC system, by the use of HPLC autosamplers. In addition, HPLC autosamplers have an injection volume and technique which is exactly the same for each injection, consequently they provide a high degree of injection volume precision. It is possible to enable sample stirring within the sampling-chamber, thus promoting homogeneity.
Sources: en.wikipedia.org
Quantitative proteomics is an analytical chemistry technique for determining the amount of various proteins, including cofactors, in a sample. The methods for protein identification and separation are identical to those used in general qualitative proteomics, but include quantification as an additional dimension. Rather than just providing lists of proteins identified in a certain sample, quantitative proteomics yields information about the physiological differences between two biological samples. For example, this approach can be used to compare samples from healthy and diseased patients. Quantitative proteomics is mainly performed by two-dimensional gel electrophoresis (2-DE), preparative native PAGE, or mass spectrometry (MS). However, a recent developed method of quantitative dot blot (QDB) analysis is able to measure both the absolute and relative quantity of individual proteins in the sample in high throughput format, thus, open a new direction for proteomic research. In contrast to 2-DE, which requires MS for the downstream protein identification, MS technology can identify and quantify the structural changes and physiological functions.
==== United States ==== 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
Vegetarian themes have also been noted in the Twilight novel (2005–2008) and film franchise (2008–2012), The Road (2006) and The Year of the Flood (2009). In March 2020, scholar Nathan Poirer reviewed Thinking Veganism in Literature and Culture: Towards a Vegan Theory, a book edited by Emelia Quinn and Benjamin Westwood, and he concluded that veganism could "infiltrate popular culture without being perceived as threatening," while noting others who contribute to the book examining vegan cinema that "challenges the normality of human supremacy by situating humans as potential prey," and stating that the essays outline ways veganism can be successful in popular culture. Reviewers said that the Netflix original film, Okja, which focused on factory farming, talks about genetically modified animals, and features a radical environmentalist group, had an impact on people's diets. Some said the film would convince audience members to become vegetarians, saying the film encourages people to eat less meat, comparing it to the impact of the documentaries Food, Inc., Blackfish, The Cove, and Cowspiracy, Jonathan Safran Foer's book, Eating Animals, the films Charlotte's Web, Babe, and Chicken Run, and to the themes of Watership Down. The film was also described as the "ultimate vegetarian film." The film's co-writer, Jon Ronson, who is also vegetarian, said that while the film will "turn people vegetarian", this was not his intention nor that of director Bong Joon-ho.
Since 1986, the restaurant has issued a calendar featuring Hooters Girls, with signings taking place in some of their restaurants. Since 1996, Hooters has held Miss Hooters International Swimsuit Pageant, a competition of Hooters Girls from around the world. The pageant once aired on Spike TV and is now livestreamed to Hooters restaurants and eventually posted on YouTube. An African-American woman won the Miss Hooters pageant for the first time in 2010: LeAngela Davis of Columbus, Ohio.
MAL-LAD, or MALLAD, also known as METAL-LAD or METALLAD, as well as 6-methallyl-6-nor-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD). The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It is also a dopamine receptor agonist, though unlike other lysergamides, does not show activity at the dopamine D1 and D5 receptors. MAL-LAD does not appear to have been assessed in animal tests of psychedelic-like activity such as drug discrimination. MAL-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University by 1987. It was subsequently further described by a group of researchers that included Nichols and other colleagues in 2025. The drug is not a controlled substance in Canada as of 2025.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.